The New England Journal of MedicineDurvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Four-hundred seventy-three of 713 patients were randomly assigned to receive durvalumab; 236 received a placebo. The 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo. Durvalumab had a response rate that was higher than placebo (28.4% vs. 16.0%), and the median response time was also longer (72.8% vs. 46.8% of the patients continued to have a response at 18 months). Durvalumab extended the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months). 29.9% of patients who received durvalumab and 26.1% of patients who received a placebo experienced adverse events of grade 3 or 4.